BRISTOL-MYERS SQUIBB CO (BRM.DE) Stock Price, Forecast & Analysis
Europe - Frankfurt Stock Exchange - FRA:BRM - US1101221083 - Common Stock
BRM.DE Key Statistics, Chart & Performance
The current stock price of BRM.DE is 47.965 EUR. In the past month the price increased by 10%. In the past year, price decreased by -11.29%.
BRM.DE Technical Analysis
ChartMill assigns a technical rating of 8 / 10 to BRM.DE. When comparing the yearly performance of all stocks, BRM.DE turns out to be only a medium performer in the overall market: it outperformed 61.06% of all stocks.
BRM.DE Fundamental Analysis
ChartMill assigns a fundamental rating of 6 / 10 to BRM.DE. BRM.DE has an average financial health and profitability rating.
BRM.DE Financial Highlights
Over the last trailing twelve months BRM.DE reported a non-GAAP Earnings per Share(EPS) of 5.63. The EPS increased by 460.68% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 12.57% | ||
| ROA | 6.23% | ||
| ROE | 32.55% | ||
| Debt/Equity | 2.41 |
BRM.DE Forecast & Estimates
34 analysts have analysed BRM.DE and the average price target is 47.16 EUR. This implies a price decrease of -1.67% is expected in the next year compared to the current price of 47.965.
For the next year, analysts expect an EPS growth of 478.44% and a revenue growth 0.22% for BRM.DE
BRM.DE Ownership
BRM.DE Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| SNW.DE | SANOFI | 10.89 | 200.95B | ||
| SAN.PA | SANOFI | 10.74 | 198.28B | ||
| 1SAN.MI | SANOFI | 10.85 | 200.25B | ||
| MRK.DE | MERCK KGAA | 15.11 | 56.04B | ||
| UNC.DE | UCB SA | 40.61 | 50.71B | ||
| UCB.BR | UCB SA | 40.42 | 50.48B | ||
| BAYN.DE | BAYER AG-REG | 7.88 | 41.35B | ||
| 1BAYN.MI | BAYER AG-REG | 7.69 | 40.33B | ||
| IPN.PA | IPSEN | 13.25 | 11.41B | ||
| TUB.BR | FINANCIERE DE TUBIZE | 110.82 | 10.26B | ||
| REC.MI | RECORDATI INDUSTRIA CHIMICA | 24.5 | 10.09B | ||
| VIRP.PA | VIRBAC SA | 20.82 | 3.03B |
Related stock screener links
About BRM.DE
Company Profile
Bristol Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. The company is headquartered in Princeton, New Jersey and currently employs 34,100 full-time employees. The company is engaged in the discovery, development and delivery of transformational medicines for patients facing serious diseases in areas: oncology, hematology, immunology, cardiovascular, neuroscience and other areas. Its growth portfolio includes Opdivo (nivolumab), Opdivo Qvantig (nivolumab and hyaluronidase-nvhy), Yervoy (ipilimumab), Reblozyl (luspatercept-aamt), Opdualag (nivolumab and relatlimab-rmbw), Breyanzi (lisocabtagene maraleucel), Camzyos (mavacamten), Zeposia (ozanimod), Abecma (idecabtagene vicleucel), and Sotyktu (deucravacitinib). Its other growth products include Onureg, Inrebic, and Empliciti. Its legacy portfolio includes Eliquis (apixaban), Revlimid (lenalidomide), Pomalyst/Imnovid (pomalidomide), Sprycel (dasatinib), and Abraxane (paclitaxel albumin-bound particles for injectable suspension). Opdivo (nivolumab) is a fully human monoclonal antibody that binds to the PD-1 on T and NKT cells.
Company Info
BRISTOL-MYERS SQUIBB CO
Route 206 And Province Line Road
Princeton NEW JERSEY US
Employees: 34100
Phone: 16092524621
BRISTOL-MYERS SQUIBB CO / BRM.DE FAQ
What does BRM do?
Bristol Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. The company is headquartered in Princeton, New Jersey and currently employs 34,100 full-time employees. The company is engaged in the discovery, development and delivery of transformational medicines for patients facing serious diseases in areas: oncology, hematology, immunology, cardiovascular, neuroscience and other areas. Its growth portfolio includes Opdivo (nivolumab), Opdivo Qvantig (nivolumab and hyaluronidase-nvhy), Yervoy (ipilimumab), Reblozyl (luspatercept-aamt), Opdualag (nivolumab and relatlimab-rmbw), Breyanzi (lisocabtagene maraleucel), Camzyos (mavacamten), Zeposia (ozanimod), Abecma (idecabtagene vicleucel), and Sotyktu (deucravacitinib). Its other growth products include Onureg, Inrebic, and Empliciti. Its legacy portfolio includes Eliquis (apixaban), Revlimid (lenalidomide), Pomalyst/Imnovid (pomalidomide), Sprycel (dasatinib), and Abraxane (paclitaxel albumin-bound particles for injectable suspension). Opdivo (nivolumab) is a fully human monoclonal antibody that binds to the PD-1 on T and NKT cells.
What is the stock price of BRISTOL-MYERS SQUIBB CO today?
The current stock price of BRM.DE is 47.965 EUR. The price decreased by -0.95% in the last trading session.
Does BRISTOL-MYERS SQUIBB CO pay dividends?
BRISTOL-MYERS SQUIBB CO (BRM.DE) has a dividend yield of 4.51%. The yearly dividend amount is currently 2.07.
How is the ChartMill rating for BRISTOL-MYERS SQUIBB CO?
BRM.DE has a ChartMill Technical rating of 8 out of 10 and a ChartMill Fundamental rating of 6 out of 10.
How is the valuation of BRISTOL-MYERS SQUIBB CO (BRM.DE) based on its PE ratio?
The PE ratio for BRISTOL-MYERS SQUIBB CO (BRM.DE) is 8.52. This is based on the reported non-GAAP earnings per share of 5.63 and the current share price of 47.965 EUR.
What is BRISTOL-MYERS SQUIBB CO worth?
BRISTOL-MYERS SQUIBB CO (BRM.DE) has a market capitalization of 97.64B EUR. This makes BRM.DE a Large Cap stock.